• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Epilepsy Partnering 2007-2013 Product Image

Epilepsy Partnering 2007-2013

  • Published: July 2013
  • Region: Global
  • 100 Pages
  • CurrentPartnering

The Epilepsy Partnering 2007-2013 provides understanding and access to the epilepsy partnering deals and agreements entered into by the worlds leading healthcare companies .

The report provides an analysis of epilepsy partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors epilepsy technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 40 links to online copies of actual epilepsy deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide READ MORE >

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in epilepsy partnering

2.1. Introduction
2.2. Epilepsy partnering over the years
2.3. Bigpharma epilepsy dealmaking activity
2.4. Epilepsy partnering by deal type
2.5. Epilepsy partnering industry sector
2.6. Epilepsy partnering by stage of development
2.7. Epilepsy partnering by technology type
2.8. Disclosed financial deal terms for Epilepsy partnering
2.8.1 Epilepsy headline values
2.8.2 Epilepsy upfront payments
2.8.3 Epilepsy milestone payments
2.8.4 Epilepsy royalty rates
Chapter 3 – Leading Epilepsy deals

3.1. Introduction
3.2. Top epilepsy deals by value
3.3. Top epilepsy deals involving bigpharma
Chapter 4 – Dealmaking directory

4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
4.4. By industry sector
Academic
Bigpharma
Biotech
Drug delivery
Medical device
Diagnostic
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
4.5. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
4.6. By technology type
Analysis
Animal models
Assays
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Cell culture
Cell therapy
Clinical testing
Diagnostic - companion
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Imaging
Industrial chemicals
In vitro models
Monoclonal antibodies
Nanotechnology
Oligonucleotide
Peptides
Personalised medicine
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Stem cells
Vaccines
Chapter 5 – Partnering resource center

5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
Appendices

Appendix 1 – Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports
Table of figures

Figure 1: Epilepsy partnering since 2007
Figure 2: Bigpharma – top 50 –epilepsy deals 2007 to 2011
Figure 3: Bigpharma epilepsy deal frequency – 2007 to 2011
Figure 4: Epilepsy partnering by deal type since 2007
Figure 5: Epilepsy partnering by industry sector since 2007
Figure 6: Epilepsy partnering by stage of development since 2007
Figure 7: Epilepsy partnering by technology type since 2007
Figure 8: Epilepsy deals with a headline value
Figure 9: Epilepsy deals with upfront payment values
Figure 10: Epilepsy deals with milestone payments
Figure 11: Epilepsy deals with royalty rates, %
Figure 12: Top epilepsy deals by value since 2007
Figure 13: Top epilepsy deals signed by bigpharma value since 2007
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions

The Epilepsy Partnering 2007-2013 report provides understanding and access to the epilepsy partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in epilepsy partnering deals
Top epilepsy deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service.

Note: Product cover images may vary from those shown

RELATED PRODUCTS